Trametinib Dimethyl Sulfoxide

CHEMBL2105741 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
693.5 g/mol
LogP
Phase
4

Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.

分子量

693.5000 g/mol

TPSA

138.00 Ų

治疗领域

作用机制

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-]

InChI

InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3

Molecular Formula

C28H29FIN5O5S

HBD / HBA

2 / 8

可旋转键数

5

重原子数

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

Yes, Trametinib Dimethyl Sulfoxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105741. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 50992434. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.